StreetInsider.com News Articles

INmune Bio and Quantum Computing Inc. partner on Alzheimer's drug research

Wed, 14 Oct 2026 08:45:56 -0400

INmune Bio Inc. (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) announced a collaboration to apply quantum computing, artificial intelligence, and data analytics to identify potential new applications for XPro1595, INmune Bio's investigational treatment for Alzheimer's disease.

The collaboration will use QCi's Dirac-3S quantum optimization machine alongside AI and conventional analytics to analyze INmune Bio's data from pre-clinical research and four clinical trials, as well as publicly available biomedical datasets. The companies intend to use the analysis to identify diseases driven by the same biological mechanisms targeted by XPro1595 and to prioritize indications with higher potential for development success.

According to the

INmune Bio and Quantum Computing Inc. partner on Alzheimer's drug research

Wed, 14 Oct 2026 08:45:56 -0400

According to the

INmune Bio and Quantum Computing Inc. partner on Alzheimer's drug research

Wed, 14 Oct 2026 08:45:56 -0400

According to the

INmune Bio and Quantum Computing Inc. partner on Alzheimer's drug research

Wed, 14 Oct 2026 08:45:56 -0400

According to the

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:45:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

BOCA RATON, Fla. and HOBOKEN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (Nasdaq: INMB) and Quantum Computing Inc. (Nasdaq: QUBT) today announced a collaboration to apply quantum computing, artificial intelligence (AI) and data analytics to identify new potential applications for

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:45:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:45:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer’s Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:45:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:30:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:30:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:30:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™

Wed, 14 Oct 2026 08:30:00 -0400

Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment indications and biomarkers for XPro
Initial engagement marks QCi's first commercial customer in pharmaceutical and biotechnology markets, expanding the application of quantum computing to drug development

Quantum Computing Inc. to Attend the Maxim Growth Summit 2026

Tue, 06 Oct 2026 08:30:00 -0400

HOBOKEN, N.J., Oct. 6, 2026 /PRNewswire/ -- Quantum Computing Inc. ("QCi" or the "Company") (Nasdaq: QUBT), a vertically integrated quantum systems company pioneering photonics and semiconductor manufacturing, today announced that Dr. Yuping Huang, Chief Executive Officer and Chris Roberts, Chief Financial Officer, will participate in the Maxim Growth Summit 2026 on October 13 at the Hard Rock Hotel in New York City. Dr. Huang and Mr.

Quantum Computing Inc. to Attend the Maxim Growth Summit 2026

Tue, 06 Oct 2026 08:30:00 -0400

Form 8-K Quantum Computing Inc. For: Oct 02

Fri, 02 Oct 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20261002/27142691.html

Quantum Computing Inc. unveils Dirac-3S with capacity for ~10,000 variables

Thu, 01 Oct 2026 08:34:19 -0400

Quantum Computing Inc. (NASDAQ: QUBT) announced the Dirac-3S, a next-generation quantum optimization machine that the company says can handle up to 9,980 variables, a tenfold increase over its current Dirac-3 system. The first customer shipment is expected in November 2026, according to a company statement.

The Dirac-3S is built around a modular architecture consisting of a compact 5U base unit that can be extended with Expansion Modules. QCi says it has demonstrated configurations supporting up to 9,980 variables using one Expansion Module, with the design intended to accommodate additional modules over time.

The system supports continuous, integer and higher-order optimization and can

Quantum Computing Inc. Announces Dirac-3S, Scaling to Nearly 10,000 Variables

Thu, 01 Oct 2026 08:30:00 -0400

Scales quantum optimization to up to nearly 10,000 variables, a 10x increase over QCi's current 1,000-variable system, while delivering faster performance, production-ready reliability and scalable manufacturing
First customer shipment of Dirac-3S upgrade expected in Q4 2026

Quantum Computing Inc. Announces Dirac-3S, Scaling to Nearly 10,000 Variables

Thu, 01 Oct 2026 08:30:00 -0400

Scales quantum optimization to up to nearly 10,000 variables, a 10x increase over QCi's current 1,000-variable system, while delivering faster performance, production-ready reliability and scalable manufacturing
First customer shipment of Dirac-3S upgrade expected in Q4 2026

The GPS-Denied Battlefield Is Creating a New Multi-Billion-Dollar Quantum Navigation Opportunity

Thu, 24 Sep 2026 09:28:00 -0400